Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA's Generics Unit

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy and Actavis are two potential bidders vying for Merck KGaA's generics drug unit, an acquisition that would solidify either company as the third largest generics drug maker in the world

You may also be interested in...

Actavis Acquires U.S. Generics, Delivery Technology Firm Abrika

Company believes the acquisition will allow for creation of a controlled-release products “center of excellence.”

Door Opens For Barr To Acquire Pliva As Actavis Bows Out Of Bidding War

Hurdles for completing the acquisition still exist for Barr, which must acquire majority of Pliva shares.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts